NAS10028,945+0.02%S&P7,552−0.45%GOLD$4,309−0.55%BTC$76,138+0.69%VIX17.71+2.97%live tape · as of 00:54 UTC
The Screen · Healthcare · Drug Manufacturers - General
Organon & Co.
OGN · the NYSE · USD · Market cap $3.6B · 10,000 employees
Organon & Co.
FAIL · Does not pass the screen
13.66 USD
At the last full screen 2026-09-15
Screened 2026-09-15 · the tape above runs as of 00:54 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Organon & Co. holds its Markdown at $13.66. The statistical read favours the sellers, held for 3 days.
As held on the ledger · 2026-09-15
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 3 days
Price at the screen
$13.66
Valuation
17.51 trailing · 3.78 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.52
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
67.18%
Below 33%
Interest-bearing debt is 67.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
14.81%
Below 49%
Money owed to the company is 14.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-15 screen. The gold marker is the market price at the same screen. A 2.5% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus None. The average target sits −16% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Low Valuation Masks Shrinking Women's Health Business
Picture a specialist supplier whose customers are quietly switching to newer options. Organon sits in that spot, delivering women's health therapies and devices across dozens of markets yet posting revenue that is already falling four percent a year.
The stock trades at just 3.7 times forward earnings with a 34 percent return on equity and clears the ethical screen. Those figures look attractive on paper, yet the margin of safety to our fair value is only four percent and the analyst median target sits below the current price, signalling limited conviction in any near-term recovery.
Revenue contraction and a thin four percent profit margin point to structural pressure rather than a temporary dip. With no moat identified and an opportunity rating of none, the risk of further erosion outweighs the headline multiple. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
OGN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-08Accumulation$13.77+1.8%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (4 analysts) rates it hold, with a mean price target of $11.
2026-08-07Accumulation$13.52+0.6%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (4 analysts) rates it hold, with a mean price target of $11.
2026-07-18Accumulation$13.44+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (4 analysts) rates it hold, with a mean price target of $11.
2026-07-03Accumulation$13.44+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$13.44Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
